Yazar "Mertoğlu, Cuma" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Evaluation of Visceral Adiposity Indexes Associated with Atherogenic Plasma Index in Individuals with Type 2 Diabetes
    (2022) Ozcicek, Fatih; Mertoğlu, Cuma; Arslan, Yusuf Kemal; Yılmaz, Sevil Karahan
    Aim: This study was aimed to investigate visceral adiposity indicators and the atherogenic index of plasma (AIP) in type 2 diabetes mellitus (T2DM) patients.Material and Methods: A total of 353 adults aged between 18 and 74 years were included in this study. Bodyweight, height, waist, and hip circumference were measured; fasting blood glucose, HbA1c, and lipid profile (total cholesterol, triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) values were analyzed. Visceral adiposity index (VAI), lipid accumulation product (LAP), body adiposity index (BAI), body shape index (ABSI), body roundness index (BRI), conicity index (CI), and AIP levels were calculated.Results: The study included 116 (32.9%) males and 237 (67.1%) females, with a mean age of 57.8±11.5 years. AIP z-scores were found to be directly related to T2DM (OR, 5.03; 95% CI: 1.95-13.01), while VAI z-scores were less associated with T2DM (OR, 1.10; 95% CI: 1.03-1.18). According to the ROC curve analysis, although the area under the curve (AUC) is weak to distinguish diabetic patients with VAI, LAP, and AIP, it is statistically significant (p<0.001, AUC: 0.619, cut-off= 5.1, 95% CI: 0.561-0.677; p=0.007, AUC: 0.583, cut-off= 63.2, 95% CI: 0.523-0.642; and p=0.001, AUC: 0.606, cut-off= 0.4, 95% CI: 0.547-0.665, respectively).Conclusion: VAI, LAP, and AIP are strong predictors of diabetes, AIP is a better predictor of predicting diabetes than VAI and LAP.
  • Küçük Resim
    Öğe
    What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality?
    (Elsevier, 2022) Huyut, Mehmet Tahir; Huyut, Zübeyir; İlkbahar, Fatih; Mertoğlu, Cuma
    It remains important to investigate the changing and impact of routine blood values (RBVs) in order to predict mortality and follow an appropriate treatment in COVID-19 patients. In the study, the importance of RBVs in the mortality of patients with COVID-19 was investigated. The changes in the biochemical, hematological, and immunological parameters of patients who recovered (n = 4364) and died (n = 233) from COVID-19 over time and their relationship with the mortality of the disease were evaluated retrospectively. Odds ratios of the parameters affecting one-month mortality were calculated by running multiple-logistic-regression analysis. The cut off values and diagnostic efficiencies of the parameters that posed a risk for mortality were obtained via receiver operating curve analysis. It was determined that the C-reactive protein (CRP), D-dimer, procalcitonin, erythrocyte-sedimentation-rate (ESR), troponin values were at abnormal levels until death occurred in the patients who died. In addition, the procalcitonin levels were consistently high in patients who died. The patients who died generally had a sustained increase in their leukocyte and neutrophil levels and biochemical variables, and an ongoing decrease in lymphopenia and eosinopenia levels. Although significant changes were observed in liver function tests, cardiac troponin, hemogram values, kidney function tests and parameters related to inflammation in deceased patients, high ESR, international-normalized-ratio (INR), prothrombin-time (PT), CRP, D-dimer, ferritin and red-cell-distribution width (RDW) values, respectively, were the most effective predictive mortality risk biomarkers of COVID-19. In addition, neutrophilia, leukocytosis, thrombocytopenia, erythrocytopenia were other risk predictors of mortality. Indicators was found in this study can be successfully used to predict mortality from COVID-19.